Ken Uchibori

11PUBLICATIONS
20CO-AUTHORS
Molecular targetsPredictive and prognostic markersLiquid biopsiesCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Jun 02, 2026
Real-World Survival Over 25 Years in Extensive-Stage Small-Cell Lung Cancer: The Impact of Immune Checkpoint Inhibitors.

|Nov 17, 2024
Targeting ErbB and tankyrase1/2 prevent the emergence of drug-tolerant persister cells in ALK-positive lung cancer.

Takaaki Fujimura, Koh Furugaki, Hayato Mizuta

|Nov 09, 2024
Serum CYFRA 21-1 as a Prognostic Marker in Non-Small-Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors.

Keiki Miyadera, Sho Kakuto, Mayu Sugai

|Feb 24, 2024
Distinction of ALK fusion gene- and EGFR mutation-positive lung cancer with tumor markers.

Takahiro Akita, Ryo Ariyasu, Sho Kakuto

|Feb 24, 2024
A macrocyclic kinase inhibitor overcomes triple resistant mutations in EGFR-positive lung cancer.

Mai Suzuki, Ken Uchibori, Tomoko Oh-Hara

|Jan 16, 2024
Efficacy of osimertinib in patients with EGFR-mutation positive non-small cell lung cancer with malignant pleural effusion.

Ayu Kiritani, Yoshiaki Amino, Ken Uchibori

Pageof 2

Frequent Collaborators

5 joint publications

Makoto Nishio

5 joint publications

Yoshiaki Amino

3 joint publications

Ryohei Katayama

2 joint publications

Jun Adachi